How a Two-Year Sanction Became Six: Ruti Aga, a Forged Prescription and Its Real Cost

The prescription carried a doctor's name. The clinic did not exist. The person who wrote it had no medical registration and was a family member of the athlete. That single fact, contained in the Athletics Integrity Unit (AIU) statement, decided the weight of the entire case. Ruti Aga's anti-doping violation was a two-year matter. Tampering with the evidence chain added four more. The total came to six. Those six years are the final chapter of her career.

There is no performance data anywhere in this story. The half marathon she won in China in March is recorded without a time. No splits, no field strength, no personal best. What exists is an administrative ledger, and that ledger is the real subject here — because in marathon journalism the question is never how fast someone ran. The question is whether the paper underneath the run holds up.

Context: a runner whose record was built on podium counts, not medals

Ruti Aga belongs to the layer of Ethiopian women's marathon running that the world does not easily remember. Her name carries three second-place finishes at World Marathon Majors. She was runner-up in Berlin in 2026, and her personal best sits around 2:18:34 — a pace that, in the history of women's marathon running, belongs to perhaps ten or twelve women who have gone under 2:20. She won the 2026 Tokyo Marathon in roughly 2:20:40. That is her most solid, most durable title.

The detail matters because Aga's position inside Ethiopia was never secure. The depth of Ethiopian women's marathon running is so extreme that a 2:18 performer cannot assume a national team place. A world-record-class generation stood above her, and a new cohort arrived every season from below. Surviving to the age of 32 in that environment is itself an achievement. Reading this case without that context would be a mistake.

Now to the substance that started it. Media reports described methylprednisolone as a "prohibited steroid" and stated that WADA classes it as performance-enhancing. That is technically wrong, and the error distorts how the whole case reads. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9, not an anabolic steroid (S1). And the crucial condition attached to S9 is that it is prohibited in-competition only, and only by injection, oral or rectal routes. A knee injection taken out of competition is entirely lawful medical treatment.

That distinction is decisive, because without it the available defence becomes invisible. If the substance had been S1, the question would be simple: it was in the body, the sanction follows. Under S9, the question is when the injection was given, by which route, and whether any residue remained on competition day. In road running the testing window opens at 23:59 the day before the race, so an injection given days earlier will be caught — but only if a genuine medical record exists and the timing can be reasoned through.

The core fact: the forgery destroyed the only defence that could have worked

According to the AIU statement, Aga cited a knee injury. Intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice among distance runners. Mechanistically, the explanation is entirely plausible. The problem is not that the story sounds impossible. The problem is that the paper produced to support it was fabricated.

Three independent verification failures are recorded together. First, the clinic that supposedly issued the prescription did not exist. Second, the person presented as the doctor had no medical registration and was a family member. Third, that person claimed to have used an old prescription pad from a former workplace — and the workplace explicitly disowned the claim. A genuine medical record does not break in three places at once.

This is where the sanction arithmetic becomes legible. Two years for the presence violation — the level that applies to a Specified Substance finding where intent is not proven. Four years for tampering — the Code's standard penalty. The sum is six. The plain meaning of that arithmetic is that the panel declined to apply a no-significant-fault reduction even at the two-year stage. The door to mitigation was open, and the athlete closed it herself.

The ban runs from 10 September, and the provisional suspension was already in effect from the same date. Reading that as a concession would be an error — it is procedural bookkeeping. Provisional suspension time always counts against the ban, so nothing was actually shaved off. By the time six years elapse she will be roughly 38. The Paris cycle has gone. The Los Angeles 2028 cycle has gone with it.

Career accounting: what survives, and what does not

One caution is required here. The March half marathon result in China, its prize money and any ranking points accrued after that date would, under standard AIU practice, be treated as annulled — even though the statement does not spell it out. But the 2026 Tokyo Marathon title predates that race, and no finding of earlier use has been made. Unless the disqualification is extended backwards, that title and the three Major runner-up finishes stay on the record.

This is where the ledger and the market diverge. The record book will say a runner won Tokyo. The sponsorship market will say the name is now a risk. Distance running already offers thin advertising space, and a six-year ban reduces that space to almost nothing. At 32, this is not a suspension. It is a retirement, described on paper as a suspension.

The contrarian reading: the substance at the centre of it proves no advantage

Here is the uncomfortable truth. Methylprednisolone is widely claimed to speed return from injury, but there is no firm evidence that it directly improves endurance. It is not an anabolic steroid. It is not erythropoietin. It does not belong to the category sitting at the centre of the darkest chapters in marathon history. The benefit of the substance on which this six-year ban rests is itself disputed. Which means the weight of the sanction does not rest on the substance at all. It rests on what happened afterwards. That does not help Aga — it establishes that the damage was self-built.

The second contrarian point is institutional. Across AIU road-running cases there is a visible pattern of tampering charges — a substance is detected, an explanation is constructed, and the explanation fails scrutiny. The enforcement frontier has shifted from detection to document verification. Aga's case is not an outlier. The informal medical networks that serve many athletes in the same training clusters seed multiple cases at once.

And the third point concerns the Chinese label-race circuit where the sample was collected. Large appearance-fee budgets, dense East African elite fields and AIU testing now occupy the same races. Every result at that tier will be read through an integrity lens. It is the irony of a system in which the athlete travels there to earn, and the test happens there too.

One more thing found no place in the AIU statement. The clinic did not exist, the doctor was unregistered, the prescription was written by a family member — yet no agent, manager or training camp is named anywhere. Whether anyone advised, accepted or submitted the document has no public answer on the record. Loading the entire weight onto a family member is convenient. It is not a complete accounting.

What comes next: the paperwork under scrutiny does not belong to one runner

The appeal route is not closed. A CAS challenge to the sanction is available, typically within about twenty-one days of the reasoned decision. But conclusions built on document verification are hard to overturn — this is not a case of sentiment, it is a case of paper.

The real question, then, is not Ruti Aga's future. It is how many more knee injuries, how many more old prescription pads, how many more clinic denials will reach the AIU's desk this year — and whether behind each of them stands another family member carrying six years alone, while the person who sent them there goes unnamed.